A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Exclusion Criteria

• •Secondary progressive MS, primary progressive MS or progressive relapsing MS
• •Prior use of interferon
• •Treatment with oral or systemic corticosteroids or adrenocorticotropic hormone (ACTH) within 4 weeks of Study Day 1 or within 7 days before the Screening MRI
• •Psychiatric disorder that is unstable or will preclude safe participation in the study
• •Significant leucopenia (white blood cell count less than 0.5 times the lower limit of normal) within 7 days of Study Day 1
• •Elevated liver function tests (Alanine transaminase \[ALT\], Aspartate transaminase \[AST\], alkaline phosphatase or total bilirubin greater than 2 times the upper limit of normal) within 7 days of Study Day 1
• •Prior cytokine or anti-cytokine therapy or glatiramer acetate within the 3 months before Study Day 1
• •Immunomodulatory or immunosuppressive therapy within the 12 months before Study Day 1, including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide and mitoxantrone
• •Previous use of cladribine or total lymphoid irradiation
• •Allergy to human serum albumin, mannitol or gadolinium diethylenetriaminepentacetic acid (DTPA)
• •Intravenous immunoglobulin or any other investigational drug or procedure in the 6 months before Study Day 1
• •Systemic disease that can interfere with subject safety, compliance or evaluation of the condition under study, such as insulin-dependent diabetes, Lyme disease, clinically significant cardiac disease or infection with human immunodeficiency virus (HIV) or Human T-cell lymphotrophic virus, Type-1 (HTLV-1)